Journal: Aktuelle Urologie
This publication reviews the use of poly(ADP-ribose) polymerase inhibitors (PARPi) combined with androgen receptor inhibitors (ARPi) in metastatic castration-resistant prostate cancer (mCRPC).
Key findings include improved radiological progression-free survival and overall survival, regardless of homologous recombination repair gene mutation status.
The report emphasizes the importance of managing treatment-related side effects, including:
- Hematological toxicities: anemia, leukopenia, and thrombocytopenia
- Non-hematological effects: fatigue, diarrhea, nausea, and constipation
Practical recommendations for uro-oncologists cover:
- Basic diagnostics
- Preventive strategies
- Dose adjustments
- Temporary treatment interruptions
- Supportive care such as blood transfusions for anemia
These measures aim to optimize patient outcomes in clinical practice.